Short Interest Update on Cytori Therapeutics Inc (CYTX)

Cytori Therapeutics Inc (CYTX) : The short interest in Cytori Therapeutics Inc (CYTX) has increased from 423,195 to 478,011 from Jul 29, 2016, to August 15, 2016, indicating that the traders are bearish on the stock. On an average, 183,220 shares are traded daily in the stock and only 3 days are left for the shorts to cover. The short open interest is 4.3% of the total shares in the hands of the public. The shorts in the stock have gone up by 54,816 shares, which is an increase of 13% over the previous reading. The short interest information was released on Wednesday Aug 24th after the market close.

Cytori Therapeutics Inc (NASDAQ:CYTX): The stock opened at $2.20 on Wednesday but the bulls could not build on the opening and the stock topped out at $2.25 for the day. The stock traded down to $2.05 during the day, due to lack of any buying support eventually closed down at $2.07 with a loss of -5.48% for the day. The stock had closed at $2.19 on the previous day. The total traded volume was 293,881 shares.


In a related news, Harris John David, officer (VP and GM Cell Therapy) of Cytori Therapeutics, Inc., executed a transaction worth $5,075 on August 10, 2016. A total of 2,500 shares were purchased at an average price of $2.03. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals, clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan and other regions. The Company offers ECCO-50, a cure for knee osteoarthritis, which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50, a cure for urinary incontinence, which is in Phase II/III of development. The Company is also developing DCCT-10, a cure for cutaneous thermal injury.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.